display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
la/mBC - TNBC - L1 - all populationla/mBC - TNBC - L1 - PDL1 positivela/mBC - TNBC - L2 - all populationla/mBC - TNBC - L2 - PDL1 positivees-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)es-BC - TNBC - NA - all populationes-BC - TNBC - NA - PDL1 positive
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitaxel IMpassion-130 ... IMpassion-130 ...
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide IMpassion-031 ...
atezolizumab plus paclitaxel IMpassion-131 ... IMpassion-131 ...
atezolizumab plus SoC IMpassion-132, ITT population IMpassion-132, PD-L1 positive population IMpassion-031 ... ALEXANDRA/IMpassion-030 NeoTrip Michel Angelo
avelumab based treatment
avelumab alone A-Brave A-Brave Stratum A
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-119 ... KEYNOTE-119 PD-L1 positive ... KEYNOTE-119 PD-L1 positive ... KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-522
pembrolizumab plus SoC KEYNOTE-355 ... KEYNOTE-355 ... KEYNOTE-355 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons